New antibody shot shows promise for eczema in early trial
NCT ID NCT05114889
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an experimental antibody injection called BSI-045B in 54 healthy volunteers and people with atopic dermatitis (eczema). The main goal was to check safety and tolerability, with some early looks at how well it might control symptoms. The study is complete, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BSI-045B (an antibody injection)
- What this could lead to
- If successful, this could point toward a new treatment option for atopic dermatitis (eczema) that reduces symptoms like itching and skin inflammation.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not effectiveness. It is small (54 participants) and may not lead to a proven treatment. Side effects or lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Scientia Clinical Research
Randwick, New South Wales, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?